51 related articles for article (PubMed ID: 2529558)
1. Tetrahydrocarbazol-1-acetic acids: new class of thromboxane receptor antagonists.
Girard Y; Yoakim-Rancourt C; Hamel P; Gillard JW; Guindon Y; Letts G; Evans J; Léveillé C; Ethier D; Lord A
Prog Clin Biol Res; 1989; 301():585-9. PubMed ID: 2529558
[No Abstract] [Full Text] [Related]
2. The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor.
Gillard JW; Morton HE; Fortin R; Yoakim C; Girard Y; Lord A; Ethier D; Leveille C; Letts G; Evans J
Prog Clin Biol Res; 1989; 301():579-83. PubMed ID: 2529557
[No Abstract] [Full Text] [Related]
3. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.
Halushka PV; Mais DE; Saussy DL
Fed Proc; 1987 Jan; 46(1):149-53. PubMed ID: 2948839
[TBL] [Abstract][Full Text] [Related]
4. 7-Oxabicyclo[2.2.1]heptane analogs as modulators of the thromboxane A2 and prostacyclin receptors.
Sprague PW; Heikes JE; Harris DN; Greenberg R
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():337-43. PubMed ID: 6303073
[No Abstract] [Full Text] [Related]
5. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
[TBL] [Abstract][Full Text] [Related]
6. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
[TBL] [Abstract][Full Text] [Related]
7. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
Mais DE; Kochel PJ; Saussy DL; Halushka PV
Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
9. Photoaffinity labelling and isoelectric focusing of the human platelet thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor.
Mais DE; Halushka PV
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():168-71. PubMed ID: 2526465
[No Abstract] [Full Text] [Related]
10. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
11. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity.
Ushikubi F; Okuma M; Kanaji K; Sugiyama T; Ogorochi T; Narumiya S; Uchino H
Thromb Haemost; 1987 Apr; 57(2):158-64. PubMed ID: 2955539
[TBL] [Abstract][Full Text] [Related]
12. [Platelet thromboxane A2 receptor].
Ushikubi F; Hirata M; Narumiya S; Okuma M
Nihon Rinsho; 1992 Feb; 50(2):264-8. PubMed ID: 1535387
[No Abstract] [Full Text] [Related]
13. ONO-AP-500-02: a non prostanoid prostaglandin I2 mimetic with inhibitory activity against thromboxane synthase.
Kondo K; Machii K; Narita M; Kawamoto A; Yamasaki S; Hamanaka N
Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():401-3. PubMed ID: 7732882
[No Abstract] [Full Text] [Related]
14. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
15. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer.
Rosentreter U; Böshagen H; Seuter F; Perzborn E; Fiedler VB
Arzneimittelforschung; 1989 Dec; 39(12):1519-21. PubMed ID: 2624597
[TBL] [Abstract][Full Text] [Related]
17. The effects of thromboxane antagonism on the transit time of platelets through the spleen.
Peters AM; Lane IF; Sinclair M; Irwin JT; McCollum CN
Thromb Haemost; 1985 Aug; 54(2):495-7. PubMed ID: 2934858
[TBL] [Abstract][Full Text] [Related]
18. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
19. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity.
Fuse I; Hattori A; Mito M; Higuchi W; Yahata K; Shibata A; Aizawa Y
Thromb Haemost; 1996 Dec; 76(6):1080-5. PubMed ID: 8972034
[TBL] [Abstract][Full Text] [Related]
20. Overview of physiological and pathophysiological effects of thromboxane A2.
Ogletree ML
Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
